{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:20:30Z","timestamp":1772256030308,"version":"3.50.1"},"reference-count":20,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.5551\/jat.65520","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T18:08:10Z","timestamp":1743185290000},"page":"1189-1202","source":"Crossref","is-referenced-by-count":0,"title":["Cholesterol Uptake Capacity as a Prognostic Marker of Cardiovascular Events for Patients with Coronary Artery Disease"],"prefix":"10.5551","volume":"32","author":[{"given":"Yusuke","family":"Yoshikawa","sequence":"first","affiliation":[{"name":"Department of Biostatistics, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Toh","sequence":"additional","affiliation":[{"name":"Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Murakami","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Sysmex Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amane","family":"Harada","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Sysmex Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeeun","family":"Kim","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Sysmex Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Sysmex Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Miwa","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, Sysmex Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Nagao","sequence":"additional","affiliation":[{"name":"Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Division of Nursing Practice, Kobe University Graduate School of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-Ichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Takegami","sequence":"additional","affiliation":[{"name":"Department of Public Health and Health Policy, The University of Tokyo"},{"name":"Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, National Cerebral and Cardiovascular Center"},{"name":"Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 1988; 8: 737-741","DOI":"10.1161\/01.ATV.8.6.737"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302: 1993-2000","DOI":"10.1001\/jama.2009.1619"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J, 2017; 38: 2478-2486","DOI":"10.1093\/eurheartj\/ehx163"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE, ACCELERATE Investigators. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med, 2017; 376: 1933-1942","DOI":"10.1056\/NEJMoa1609581"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tall AR, Rader DJ. Trials and Tribulations of CETP Inhibitors. Circ Res, 2018; 122: 106-112","DOI":"10.1161\/CIRCRESAHA.117.311978"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol, 2008; 51: 2199-2211","DOI":"10.1016\/j.jacc.2008.03.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135","DOI":"10.1056\/NEJMoa1001689"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med, 2014; 371: 2383-2393","DOI":"10.1056\/NEJMoa1409065"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Toh R. Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application. J Atheroscler Thromb, 2019; 26: 111-120","DOI":"10.5551\/jat.RV17028"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Harada A, Toh R, Murakami K, Kiriyama M, Yoshikawa K, Miwa K, Kubo T, Irino Y, Mori K, Tanaka N, Nishimura K, Ishida T, Hirata K-I. Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment. J Appl Lab Med, 2017; 2: 186-200","DOI":"10.1373\/jalm.2016.022913"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Murakami K, Harada A, Toh R, Kubo T, Miwa K, Kim J, Kiriyama M, Iino T, Nishikawa Y, Uno S-N, Akatsuchi K, Nagao M, Ishida T, Hirata K-I. Fully automated immunoassay for cholesterol uptake capacity to assess high-density lipoprotein function and cardiovascular disease risk. Sci Rep, 2023; 13: 1899","DOI":"10.1038\/s41598-023-28953-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Fujimoto D, Otake H, Kawamori H, Toba T, Nagao M, Nakano S, Tanimura K, Takahashi Y, Fukuyama Y, Kakizaki S, Nakamura K, Harada A, Murakami K, Iino T, Toh R, Hirata K-I. Cholesterol uptake capacity: A new measure of high-density lipoprotein functionality as a predictor of subsequent revascularization in patients undergoing percutaneous coronary intervention. Atherosclerosis, 2022; 345: 44-50","DOI":"10.1016\/j.atherosclerosis.2022.01.014"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Genest J, Choi HY. The Cholesterol Uptake Capacity: The search for scalable HDL function tests continues. Atherosclerosis, 2022; 345: 39-40","DOI":"10.1016\/j.atherosclerosis.2022.02.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, Kotani K, Kiyama M, Yamada M, Ishikawa S, Murakami Y, Miura K, Ueshima H, Okamura T, Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH\u2013JAPAN) Research Group. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol, 2018; 12: 674-684.e5","DOI":"10.1016\/j.jacl.2018.01.014"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Miyamoto-Sasaki M, Yasuda T, Monguchi T, Nakajima H, Mori K, Toh R, Ishida T, Hirata K-I. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb, 2013; 20: 708-716","DOI":"10.5551\/jat.17210"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Triolo M, Annema W, de Boer JF, Tietge UJF, Dullaart RPF. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest, 2014; 44: 240-248","DOI":"10.1111\/eci.12226"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kini AS, Vengrenyuk Y, Shameer K, Maehara A, Purushothaman M, Yoshimura T, Matsumura M, Aquino M, Haider N, Johnson KW, Readhead B, Kidd BA, Feig JE, Krishnan P, Sweeny J, Milind M, Moreno P, Mehran R, Kovacic JC, Baber U, Dudley JT, Narula J, Sharma S. Intracoronary imaging, cholesterol efflux, and transcriptomes after intensive statin treatment: The YELLOW II study. J Am Coll Cardiol, 2017; 69: 628-640","DOI":"10.1016\/j.jacc.2016.10.029"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nagano Y, Otake H, Toba T, Kuroda K, Shinkura Y, Tahara N, Tsukiyama Y, Yanaka K, Yamamoto H, Nagasawa A, Onishi H, Sugizaki Y, Takeshige R, Harada A, Murakami K, Kiriyama M, Oshita T, Irino Y, Kawamori H, Ishida T, Toh R, Shinke T, Hirata K-I. Impaired Cholesterol-Uptake Capacity of HDL Might Promote Target-Lesion Revascularization by Inducing Neoatherosclerosis After Stent Implantation. J Am Heart Assoc, 2019; 8: e011975","DOI":"10.1161\/JAHA.119.011975"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Seto Y, Nagao M, Iino T, Harada A, Murakami K, Miwa K, Shinohara M, Nishimori M, Yoshikawa S, Asakura J, Fujioka T, Ishida T, Hirata K-I, Toh R. Impaired Cholesterol Uptake Capacity in Patients with Hypertriglyceridemia and Diabetes Mellitus. J Appl Lab Med, 2024. doi: 10.1093\/jalm\/jfae024","DOI":"10.1093\/jalm\/jfae024"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Haraguchi Y, Toh R, Hasokawa M, Nakajima H, Honjo T, Otsui K, Mori K, Miyamoto-Sasaki M, Shinohara M, Nishimura K, Ishida T, Hirata K-I. Serum myeloperoxidase\/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis, 2014; 234: 288-294","DOI":"10.1016\/j.atherosclerosis.2014.03.009"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/9\/32_65520\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:03:25Z","timestamp":1772251405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/9\/32_65520\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65520","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"65520"}}